IL18BP and adult-onset Still disease: Recombinant IL-18BP (tadekinig alfa) has previously been found to be safe in a small phase II open-label trial (NCT02398435) of ten adults with AOSD and for compassionate use in two adults suffering from AOSD [17,18].